Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes

Patrick Serruys, Yoshinobu Onuma, John Ormiston, Bernard de Bruyne, Evelyn Regar, Dariusz Dudek, Leif Thuesen, Pieter Smits, Bernard Chevalier, Dougal McClean, Jacques Koolen, Stephan Windecker, Robert Whitbourn, Ian Meredith, Cecile Dorange, Susan Veldhof, Karine Miquel-Hebert, Richard Rapoza, Hector Garcia-Garcia

Research output: Contribution to journalArticleResearchpeer-review

300 Citations (Scopus)


BACKGROUND: The first generation of the bioresorbable everolimus drug-eluting vascular scaffold showed signs of shrinkage at 6 months, which largely contributed to late luminal loss. Nevertheless, late luminal loss was less than that observed with bare metal stents. To maintain the mechanical integrity of the device up to 6 months, the scaffold design and manufacturing process of its polymer were modified.
Original languageEnglish
Pages (from-to)2301 - 2312
Number of pages12
Issue number22
Publication statusPublished - 2010

Cite this